GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Icon PLC (NAS:ICLR) » Definitions » Cyclically Adjusted Price-to-FCF

Icon (ICLR) Cyclically Adjusted Price-to-FCF : 40.20 (As of Apr. 28, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Icon Cyclically Adjusted Price-to-FCF?

As of today (2024-04-28), Icon's current share price is $308.31. Icon's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $7.67. Icon's Cyclically Adjusted Price-to-FCF for today is 40.20.

The historical rank and industry rank for Icon's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ICLR' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 27.65   Med: 47.77   Max: 69.75
Current: 40.19

During the past years, Icon's highest Cyclically Adjusted Price-to-FCF was 69.75. The lowest was 27.65. And the median was 47.77.

ICLR's Cyclically Adjusted Price-to-FCF is ranked worse than
60.32% of 63 companies
in the Medical Diagnostics & Research industry
Industry Median: 33.84 vs ICLR: 40.19

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Icon's adjusted free cash flow per share data for the three months ended in Mar. 2024 was $3.603. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $7.67 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Icon Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Icon's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icon Cyclically Adjusted Price-to-FCF Chart

Icon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.85 47.41 57.05 31.08 38.40

Icon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.19 37.09 34.62 38.40 43.80

Competitive Comparison of Icon's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Icon's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icon's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Icon's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Icon's Cyclically Adjusted Price-to-FCF falls into.



Icon Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Icon's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=308.31/7.67
=40.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Icon's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Icon's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=3.603/120.1096*120.1096
=3.603

Current CPI (Mar. 2024) = 120.1096.

Icon Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.974 100.773 -1.161
201409 1.597 100.474 1.909
201412 1.031 99.576 1.244
201503 0.815 99.975 0.979
201506 0.238 100.573 0.284
201509 1.028 100.274 1.231
201512 1.831 99.676 2.206
201603 0.919 99.676 1.107
201606 0.100 101.072 0.119
201609 0.748 100.274 0.896
201612 2.080 99.676 2.506
201703 2.728 100.374 3.264
201706 0.041 100.673 0.049
201709 1.831 100.474 2.189
201712 1.547 100.075 1.857
201803 0.585 100.573 0.699
201806 0.552 101.072 0.656
201809 2.130 101.371 2.524
201812 0.750 100.773 0.894
201903 1.618 101.670 1.911
201906 0.212 102.168 0.249
201909 2.695 102.268 3.165
201912 2.352 102.068 2.768
202003 2.439 102.367 2.862
202006 2.037 101.769 2.404
202009 1.976 101.072 2.348
202012 3.426 101.072 4.071
202103 1.936 102.367 2.272
202106 2.163 103.364 2.513
202109 3.399 104.859 3.893
202112 2.918 106.653 3.286
202203 2.509 109.245 2.759
202206 1.869 112.734 1.991
202209 2.139 113.431 2.265
202212 -1.412 115.425 -1.469
202303 1.801 117.618 1.839
202306 2.079 119.611 2.088
202309 3.765 120.708 3.746
202312 4.687 120.110 4.687
202403 3.603 120.110 3.603

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Icon  (NAS:ICLR) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Icon Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Icon's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Icon (ICLR) Business Description

Traded in Other Exchanges
Address
South County Business Park, Leopardstown, Dublin, IRL, D18 X5R3
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.